Table 1 The relationship between S100A2 mRNA expression and clinical characteristics in endometrial carcinoma

Clinical stage, n (%)

0.028

  Stage I

186 (33.7%)

156 (28.3%)

  Stage II

22 (4%)

29 (5.3%)

  Stage III

52 (9.4%)

78 (14.1%)

  Stage IV

16 (2.9%)

13 (2.4%)

Primary therapy outcome, n (%)

0.864

  PD

11 (2.3%)

9 (1.9%)

  SD

2 (0.4%)

4 (0.8%)

  PR

6 (1.2%)

6 (1.2%)

  CR

218 (45.4%)

224 (46.7%)

Race, n (%)

0.549

  Asian

10 (2%)

10 (2%)

  Black or African

  American

60 (11.8%)

48 (9.5%)

  White

188 (37.1%)

191 (37.7%)

Age, n (%)

0.766

  <=60

101 (18.4%)

105 (19.1%)

  >60

174 (31.7%)

169 (30.8%)

Weight, n (%)

0.727

  <=80

124 (23.5%)

119 (22.5%)

  >80

140 (26.5%)

145 (27.5%)

BMI, n (%)

0.219

  <=30

114 (22%)

98 (18.9%)

  >30

147 (28.3%)

160 (30.8%)

Histological type, n (%)

0.014

  Endometrioid

220 (39.9%)

190 (34.4%)

  Mixed

9 (1.6%)

15 (2.7%)

  Serous

47 (8.5%)

71 (12.9%)

Residual tumor, n (%)

0.962

  R0

198 (47.9%)

177 (42.9%)

  R1

12 (2.9%)

10 (2.4%)

  R2

8 (1.9%)

8 (1.9%)

Histologic grade, n (%)

0.658

  G1

51 (9.4%)

47 (8.7%)

  G2

63 (11.6%)

57 (10.5%)

  G3

156 (28.8%)

167 (30.9%)

Tumor invasion(%), n (%)

0.402

  <50

134 (28.3%)

125 (26.4%)

  >=50

102 (21.5%)

113 (23.8%)

Menopause status, n (%)

0.038

  Pre

23 (4.5%)

12 (2.4%)

  Peri

5 (1%)

12 (2.4%)

  Post

221 (43.7%)

233 (46%)

Hormones therapy, n (%)

0.578

  No

143 (41.6%)

154 (44.8%)

  Yes

20 (5.8%)

27 (7.8%)

Radiation therapy, n (%)

0.177

  No

148 (28.1%)

131 (24.9%)

  Yes

116 (22%)

132 (25%)

Diabetes, n (%)

0.158

  No

155 (34.4%)

173 (38.4%)

  Yes

68 (15.1%)

55 (12.2%)